SEARCH:
Signup to create an account
test
Icahn Ups the Ante in Bid to Spin Off PayPal

Activist investor Carl Icahn upped the ante in its bid to push eBay Inc. (NASDAQ: EBAY) to spin off PayPal. In a DEF14A filing with the SEC, Mr. Icahn said that the complete disregard for accountability at eBay is the most blatant he's ever seen and strongly urged a number of changes designed to unlock value.

test
Two Ways to Invest in the Wireless Revolution

Most people thought Matt Rogers and Tony Fadell were crazy to leave Apple Inc. (NASDAQ: AAPL) in 2010 to try and start-up a small company focused on wireless home automation.


test
RXi Pharmaceuticals Moves Up to the NASDAQ Stock Exchange

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has made a lot of progress.

Recent Insider Filings
FOUNDATION MEDICINE, INC. (KAFKA STEVEN J.)
OPKO HEALTH, INC. (FROST PHILLIP MD ET AL)
TIGER X MEDICAL, INC. (FROST PHILLIP MD ET AL)
AUTOLIV INC (LOFVENHOLM JOHAN)
AUTOLIV INC (NELLIS ANTHONY J)
AUTOLIV INC (CHANG KET LEONG)
SEACOAST BANKING CORP OF FLORIDA (DAUM JULIE H)
SEACOAST BANKING CORP OF FLORIDA (CROOK MICHAEL)
SEACOAST BANKING CORP OF FLORIDA (CULBRETH H GILBERT JR)



Executive Interview
Aethlon Medical (OTCQB: AEMD)
In this episode of the SECFilings.com Executive Interview Series we speak to Dr. Douglas Taylor, Chief Scientific Officer of Exosome Sciences, wholly owned subsidiary of Aethlon Medical.


Executive Interview
Theralase Technologies (OTC: TLTFF)
In this episode we will be talking to Mr. Roger Dumoulin-White, President & CEO of Theralase Technologies. Theralase designs, manufactures and markets patented, super-pulsed laser technology used in eliminating pain and destroying cancer.


Executive Interview
Galectin Therapeutics (NASDAQ: GALT)
In this SECFilings.com Executive Interview we speak with Mr. Jim Czirr, Executive Chairman of Galectin Therapeutics.